(1/5) This is perhaps not urgent but it is important. Clinical cancer research will almost certainly take a hit over the next few months. There will likely be a decrease in trial accruals and the pace of progress will slow. Our society can't afford this. @ASCO @BladderCancerUS (2/5) However, the impact will be magnified, perhaps exponentially, by the protocol deviations and violations for missed and delayed visits leading to countless queries, EDC revisions, monitor interactions, etc.